AxoGen, Inc. (NASDAQ:AXGN) reported Q2 2017 earnings this Afternoon, coming in at ($0.06) per share, beating Wall Street’s estimates of ($0.08) per Share. Revenue for the quarter came in at $15.20 million beating analyst estimates of $14.40 million
Analyst Coverage For AxoGen, Inc. (NASDAQ:AXGN)
These are 6 Buy Ratings .
The current consensus rating for AxoGen, Inc. (NASDAQ:AXGN) is Buy (Score: 3.00) with a consensus target price of $15.90 , a potential (4.95% upside)Recent Insider Trading for AxoGen, Inc. (NASDAQ:AXGN)
- On 10/7/2016 Amy Mcbride Wendell, Director, bought 13,333 with an average share price of $7.50 per share and the total transaction amounting to $99,997.50.
- On 10/7/2016 John P Engels, VP, bought 4,000 with an average share price of $7.50 per share and the total transaction amounting to $30,000.00.
- On 10/7/2016 Karen L Zaderej, CEO, bought 10,000 with an average share price of $7.50 per share and the total transaction amounting to $75,000.00.
- On 10/7/2016 Peter J Mariani, CFO, bought 3,333 with an average share price of $7.50 per share and the total transaction amounting to $24,997.50.
- On 8/9/2016 Joseph M Mandato, Director, sold 149,618 with an average share price of $8.54 per share and the total transaction amounting to $1,277,737.72.
- On 8/8/2016 Joseph M Mandato, Director, sold 107,450 with an average share price of $8.63 per share and the total transaction amounting to $927,293.50.
Recent Trading for AxoGen, Inc. (NASDAQ:AXGN) Shares of AxoGen, Inc. closed the previous trading session at 15.15 down -0.50 -3.19% with 352,594 shares trading hands.